Handelsavisen
prelaunch
Companies ›Healthcare ›331920.KQ
33
331920.KQ — KOSDAQ Biotechnology & Medical Research

331920.Kq

$14 900,00
Open in Charts → Attach watcher ⌖
— —
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
121,6B KRW
P/E
—
EV / Rev
—
Div yield
—
Op margin
-57,6 %
ROE
-17,5 %
Net margin
-70,0 %
Debt / equity
0,02
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the healthcare diagnostics segment, providing products and services related to medical research and diagnostics.

Business. The company operates in the healthcare diagnostics segment, providing products and services related to medical research and diagnostics.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-17,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 331920.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 331920.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare diagnostics segment, providing products and services related to medical research and diagnostics.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 6.58 and cash and equivalents amounting to 3,213,173,790 KRW. The price-to-book ratio is 5.5, indicating that the market values the company at a premium to its book value. The company's debt-to-equity ratio is 0.02, suggesting a low reliance on debt financing.

    Profitability metrics show a challenging performance, with a return on equity of -17.54% and a return on assets of -16.54%. The company reported a net loss of 4,036,459,740 KRW and an operating loss of 3,324,045,670 KRW, indicating significant operational challenges. Gross profit of 2,867,379,090 KRW is a positive sign, but it is insufficient to offset the operating and net losses.

    The company's revenue is concentrated in a single segment, as disclosed in the financial snapshot. There is no detailed geographic breakdown provided, but the company's operations are primarily based in South Korea. The lack of geographic diversification may pose a concentration risk.

    The company's growth trajectory is uncertain, with a significant operating cash outflow of 3,597,118,850 KRW and a free cash flow of -3,482,231,730 KRW. Analyst estimates suggest a mean revenue of 12,100,000,000 KRW, which is higher than the last actual revenue of 5,265,260,000 KRW, indicating potential for growth. However, the mean EBIT estimate of -200,000,000 KRW suggests continued operational losses.

    The company's risk assessment indicates low liquidity and dilution risks. No immediate filing-based liquidity or dilution flags were detected, and the dilution potential is low. The company's capital structure is relatively stable, with a low debt-to-equity ratio and a strong cash position.

    Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's capital expenditure of -165,787,350 KRW suggests a modest investment in long-term assets. The company's financial performance and strategic direction remain under scrutiny due to the significant net and operating losses.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 6.58 and a significant cash reserve.
    • Profitability is a major concern, with a return on equity of -17.54% and a net loss of 4,036,459,740 KRW.
    • The company's revenue is concentrated in a single segment, which may pose a concentration risk.
    • Analyst estimates suggest potential for revenue growth, but continued operational losses are expected.
    • The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $14 900,00
    Market cap
    $126.63B
    Enterprise valueⓘ
    $123.79B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    5.5x
    P / Tangible bookⓘ
    5.5x
    Tangible book
    $23.02B
    Net cashⓘ
    $2.84B
    Current ratioⓘ
    6.6
    Debt / equityⓘ
    0.0
    ROAⓘ
    -16.5%
    ROEⓘ
    -17.5%
    Cash conversionⓘ
    89.0%
    CapEx / revenueⓘ
    -2.9%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Operating income · consensus-200,0M KRW
    Revenue surprise
    −56,5 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-57,6 %Above median
    Net Margin-70,0 %Above median
    ROE-17,5 %Below median
    Capex / Rev-2,9 %Above median
    D/E0,02Above median
    Cash Conv0,89Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 331920.KQ Market data — financials · 2026-05-26
    • Celemics Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    331920.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage